Oslo ,24 January 2020 -Navamedic ASA (OSE: NAVA), today announces it has entered into an agreement withAlimentary Health for the launch of Alflorex®, a unique product for irritable bowel syndrome (IBS), inthe Netherlands in 2H 2020. InDecember 2019 ,Navamedic launched Alflorex® inDenmark . "We are pleased to announce the agreement withAlimentary Health , expanding our distribution of Alflorex® tothe Netherlands , a key growth market forNavamedic . About 10-15% of the population have IBS symptoms, and by introducing Alflorex® in more markets we are contributing to improved quality of life by helping IBS sufferers to take back control of their gut health," saysKathrine Gamborg Andreassen , CEO ofNavamedic . Based on a strategic partnership withPrecisionBiotics Ltd ,Navamedic is already distributing Alflorex® to pharmacies inNorway and inDecember 2019 , the company launched the product in pharmacies inDenmark . In addition,Navamedic has the territory rights to launch the product inIceland . "Expansion of existing products to new geographies proves the attractiveness ofNavamedic's highly scalable market access platform, and is a recognition of our expertise in introducing, positioning and marketing of products across categories. Both the consumer health gastro therapeutic area and the probiotic market is underdeveloped in our markets, and we aim to drive growth in this market with this unique product," says Gamborg Andreassen.Alimentary Health is the owner of Alflorex® and part of thePrecisionBiotics Group , who is developing unique bacteria cultures that have been specifically researched and rigorously tested for specific indications. Alflorex® for IBS is classified as a medical Class IIb and contains the patented bacterial strain, Bifidobacterium Longum 35624®. The 35624® bacteria culture is clinically proven to reduce symptoms for IBS, including bloating and gas, abdominal pain, diarrhea and constipation. For further information, please contact:Kathrine Gamborg Andreassen , CEO,Navamedic Mobile: +47 951 78 680 E-mail: kathrine@navamedic.com Lars Hjarrand, CFO,Navamedic Mobile: +47 917 62 842 E-mail: lars.hjarrand@navamedic.com
Click here for more information
© Oslo Bors ASA, source